Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $26.79 in the prior trading day, Beta Bionics Inc (NASDAQ: BBNX) closed at $26.78, down -0.04%. In other words, the price has decreased by -$0.04 from its previous closing price. On the day, 1.1 million shares were traded. BBNX stock price reached its highest trading level at $28.76 during the session, while it also had its lowest trading level at $26.0.
Ratios:
Our goal is to gain a better understanding of BBNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 10.64. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 01, 2025, Goldman Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $26.
On June 16, 2025, Truist started tracking the stock assigning a Buy rating and target price of $26.Truist initiated its Buy rating on June 16, 2025, with a $26 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 03 ’25 when Feider Stephen sold 4,982 shares for $21.69 per share. The transaction valued at 108,076 led to the insider holds 44,041 shares of the business.
Feider Stephen sold 15,018 shares of BBNX for $311,806 on Oct 01 ’25. The Chief Financial Officer now owns 44,041 shares after completing the transaction at $20.76 per share. On Oct 03 ’25, another insider, Stephen Feider, who serves as the Officer of the company, bought 4,982 shares for $21.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 1178979712 and an Enterprise Value of 957979648. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.31 while its Price-to-Book (P/B) ratio in mrq is 4.00. Its current Enterprise Value per Revenue stands at 10.816 whereas that against EBITDA is -14.229.
Stock Price History:
Over the past 52 weeks, BBNX has reached a high of $30.47, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is 23.89%, while the 200-Day Moving Average is calculated to be 55.64%.
Shares Statistics:
The stock has traded on average 840.29K shares per day over the past 3-months and 991120 shares per day over the last 10 days, according to various share statistics. A total of 43.99M shares are outstanding, with a floating share count of 33.17M. Insiders hold about 24.65% of the company’s shares, while institutions hold 88.49% stake in the company. Shares short for BBNX as of 1760486400 were 4169413 with a Short Ratio of 4.96, compared to 1757894400 on 3882499. Therefore, it implies a Short% of Shares Outstanding of 4169413 and a Short% of Float of 10.83.
Earnings Estimates
. The current rating of Beta Bionics Inc (BBNX) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.38 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.97 and -$2.05 for the fiscal current year, implying an average EPS of -$2.02. EPS for the following year is -$1.67, with 4.0 analysts recommending between -$1.45 and -$1.93.
Revenue Estimates
7 analysts predict $28.91M in revenue for. The current quarter. It ranges from a high estimate of $29.8M to a low estimate of $28M. As of. The current estimate, Beta Bionics Inc’s year-ago sales were $20.44MFor the next quarter, 7 analysts are estimating revenue of $27.64M. There is a high estimate of $30.67M for the next quarter, whereas the lowest estimate is $25.85M.
A total of 7 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $97.9M, while the lowest revenue estimate was $96.6M, resulting in an average revenue estimate of $97.17M. In the same quarter a year ago, actual revenue was $65.12MBased on 10 analysts’ estimates, the company’s revenue will be $129.71M in the next fiscal year. The high estimate is $143.98M and the low estimate is $113.1M.
